指南与共识慢阻肺

Fleischner学会立场文件:CT密度测定在临床试验中评估肺气肿的应用

The Use of Computed Tomography Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society.
指南 / 共识 · Am J Respir Crit Care Med · 2025-01-01

该立场文件基于系统文献综述,评估CT密度测定作为肺气肿诊断、预后和疾病进展监测生物标志物的证据,并制定实施标准。低衰减区百分比(<-950 HU)是经验证、高重复性的诊断和预后生物标志物;推荐使用容积校正肺密度进行疾病监测。两者在规范技术下扫描-重扫描组内相关系数为0.99。

要点

  • 低衰减区百分比(<-950 HU)可作为肺气肿诊断和预后生物标志物。
  • 容积校正肺密度推荐用于肺气肿疾病进展监测。
  • 临床试验应采用标准化CT技术、合适受试者选择和纵向容积校正肺密度评估。

核心结论

  • CT密度测定指标是经验证、高重复性的肺气肿诊断和预后生物标志物。
  • 容积校正肺密度推荐用于疾病监测。

研究设计与样本

  • Fleischner学会立场文件,基于系统文献综述回答三个关键问题。

主要发现

  • 低衰减区百分比(<-950 HU)等肺气肿指标是经验证、高重复性的诊断和预后生物标志物。
  • 容积校正肺密度推荐用于疾病监测。
  • 规范技术下两项指标的扫描-重扫描组内相关系数均为0.99。

关键数值与推荐

  • 低衰减区百分比阈值:低于-950 Hounsfield单位。
  • 扫描-重扫描组内相关系数:0.99(规范技术下)。

临床怎么用

  • 临床试验中采用标准化CT技术、合适受试者选择和纵向容积校正肺密度评估。

局限性

  • 讨论了CT物理、技术及变异来源(技术因素、生理变化和软件分析)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emphysema's significant morbidity and mortality underscore the need for reliable outcome metrics in clinical trials. However, commonly accepted chronic obstructive pulmonary disease outcome measures do not adequately capture emphysema severity or progression. Computed tomography (CT) metrics have been validated as accurate indicators of pathological emphysema and predictors of chronic obstructive pulmonary disease progression, exacerbations, and mortality. This position paper reviews the evidence supporting CT densitometry as a biomarker for emphysema, establishes implementation standards, and highlights areas for future research. A systematic literature review addressed three key questions: whether CT densitometry can be used as a diagnostic biomarker of emphysema, whether CT densitometry can be used as a prognostic biomarker, and whether longitudinal change in densitometry can be used as a disease progression monitoring biomarker. Emphysema metrics, such as the percentage of low attenuation areas below -950 Hounsfield units, are validated, highly reproducible diagnostic and prognostic biomarkers. Volume-adjusted lung density is recommended for disease monitoring. Both metrics demonstrate a scan-rescan intraclass correlation coefficient of 0.99 with proper technique. The paper also discusses relevant CT physics, techniques, and sources of variation, including technical factors, physiological changes, and software analysis. Key recommendations for clinical trials include using standardized CT techniques, proper subject selection, and longitudinal evaluation with volume-adjusted lung density.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. San José Estépar R, Barr RG, Fain SB, et al. The Use of Computed Tomography Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society. Am J Respir Crit Care Med. 2025. PMID: 40126404. doi:10.1164/rccm.202410-2012SO

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。